AU2010205493A1 - Methods employing non-coding RNA expression assays - Google Patents
Methods employing non-coding RNA expression assays Download PDFInfo
- Publication number
- AU2010205493A1 AU2010205493A1 AU2010205493A AU2010205493A AU2010205493A1 AU 2010205493 A1 AU2010205493 A1 AU 2010205493A1 AU 2010205493 A AU2010205493 A AU 2010205493A AU 2010205493 A AU2010205493 A AU 2010205493A AU 2010205493 A1 AU2010205493 A1 AU 2010205493A1
- Authority
- AU
- Australia
- Prior art keywords
- expression
- coding rnas
- interventions
- intervention
- biological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 233
- 108091027963 non-coding RNA Proteins 0.000 title claims abstract description 114
- 102000042567 non-coding RNA Human genes 0.000 title claims abstract description 114
- 238000000034 method Methods 0.000 title claims abstract description 90
- 238000003556 assay Methods 0.000 title claims abstract description 51
- 230000000694 effects Effects 0.000 claims abstract description 77
- 239000002679 microRNA Substances 0.000 claims description 68
- 239000003795 chemical substances by application Substances 0.000 claims description 60
- 238000012360 testing method Methods 0.000 claims description 59
- 230000001225 therapeutic effect Effects 0.000 claims description 55
- 210000000130 stem cell Anatomy 0.000 claims description 17
- 230000002596 correlated effect Effects 0.000 claims description 15
- 230000007246 mechanism Effects 0.000 claims description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 13
- 230000010534 mechanism of action Effects 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 11
- 230000004069 differentiation Effects 0.000 claims description 10
- 230000002939 deleterious effect Effects 0.000 claims description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 229920002521 macromolecule Polymers 0.000 claims description 3
- 108091070501 miRNA Proteins 0.000 claims description 3
- 231100000027 toxicology Toxicity 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 description 121
- 210000004027 cell Anatomy 0.000 description 27
- 238000010839 reverse transcription Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000000513 principal component analysis Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003596 drug target Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000010208 microarray analysis Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 150000005829 chemical entities Chemical class 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 3
- 101710086015 RNA ligase Proteins 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003684 drug solvent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000583 toxicological profile Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 108010051489 calin Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000009511 drug repositioning Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003065 hierarchial clustering Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 238000003253 miRNA assay Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0900809.5 | 2009-01-19 | ||
| GB0900809A GB0900809D0 (en) | 2009-01-19 | 2009-01-19 | Methods employing non-coding RNA expression assays |
| GB0917708.0 | 2009-10-09 | ||
| GB0917708A GB0917708D0 (en) | 2009-10-09 | 2009-10-09 | Methods employing non-coding rna expression assays |
| PCT/GB2010/000076 WO2010082039A1 (en) | 2009-01-19 | 2010-01-19 | Methods employing non-coding rna expression assays |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2010205493A1 true AU2010205493A1 (en) | 2011-09-08 |
Family
ID=42078007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010205493A Abandoned AU2010205493A1 (en) | 2009-01-19 | 2010-01-19 | Methods employing non-coding RNA expression assays |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9074241B2 (enExample) |
| EP (2) | EP2387617B1 (enExample) |
| JP (1) | JP2012514994A (enExample) |
| KR (1) | KR20110138341A (enExample) |
| CN (1) | CN102356163A (enExample) |
| AU (1) | AU2010205493A1 (enExample) |
| CA (1) | CA2787218A1 (enExample) |
| IL (1) | IL214154A (enExample) |
| SG (2) | SG196843A1 (enExample) |
| WO (1) | WO2010082039A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201014049D0 (en) * | 2010-08-23 | 2010-10-06 | Sistemic Uk | Cell characterisation |
| CN108319814B (zh) * | 2018-01-29 | 2018-12-14 | 中国科学院生物物理研究所 | 基于染色体空间相互作用预测长非编码rna生物学功能的方法 |
| CN111899788B (zh) * | 2020-07-06 | 2023-08-18 | 李霞 | 一种非编码rna调控疾病风险靶通路的识别方法及系统 |
| CN113593700B (zh) * | 2021-08-06 | 2024-02-27 | 江苏师范大学 | 分析肺癌进展的方法、装置、设备、介质及程序产品 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010081098A (ko) * | 1998-10-27 | 2001-08-27 | 추후제출 | 유전자 발현 패턴의 탐지 및 분류를 강화하기 위한공통-조절 유전자세트를 이용하는 방법 |
| WO2005056761A2 (en) * | 2003-12-05 | 2005-06-23 | Massachusetts Institute Of Technology | REAGENTS AND METHODS FOR IDENTIFICATION OF RNAi PATHWAY GENES AND CHEMICAL MODULATORS OF RNAi |
| CA2562390C (en) * | 2004-04-07 | 2014-12-02 | Exiqon A/S | Novel methods for quantification of micrornas and small interfering rnas |
| US20100310583A1 (en) | 2007-01-31 | 2010-12-09 | Immune Disease Institute | Let-7 microrna and mimetics thereof as therapeutics for cancer |
| CA2678919A1 (en) | 2007-03-27 | 2008-10-02 | Ranit Aharonov | Gene expression signature for classification of cancers |
| WO2008154098A2 (en) * | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
| US8367318B2 (en) * | 2007-07-23 | 2013-02-05 | Dharmacon, Inc. | Screening of micro-RNA cluster inhibitor pools |
| CA2676113C (en) * | 2007-07-25 | 2014-07-08 | University Of Louisville Research Foundation, Inc. | Exosome-associated microrna as a diagnostic marker |
| JP2011505143A (ja) * | 2007-11-30 | 2011-02-24 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | マイクロｒｎａ発現プロファイリング及び肺癌における末梢血ターゲティング |
-
2010
- 2010-01-19 JP JP2011545794A patent/JP2012514994A/ja active Pending
- 2010-01-19 CA CA2787218A patent/CA2787218A1/en not_active Abandoned
- 2010-01-19 AU AU2010205493A patent/AU2010205493A1/en not_active Abandoned
- 2010-01-19 SG SG2014004279A patent/SG196843A1/en unknown
- 2010-01-19 EP EP10705399.3A patent/EP2387617B1/en active Active
- 2010-01-19 EP EP12169171.1A patent/EP2492357B1/en active Active
- 2010-01-19 SG SG2011052065A patent/SG173042A1/en unknown
- 2010-01-19 KR KR1020117019196A patent/KR20110138341A/ko not_active Withdrawn
- 2010-01-19 WO PCT/GB2010/000076 patent/WO2010082039A1/en not_active Ceased
- 2010-01-19 US US13/145,208 patent/US9074241B2/en active Active
- 2010-01-19 CN CN2010800129012A patent/CN102356163A/zh active Pending
-
2011
- 2011-07-18 IL IL214154A patent/IL214154A/en active IP Right Grant
-
2015
- 2015-07-06 US US14/792,057 patent/US20160002722A1/en not_active Abandoned
-
2016
- 2016-11-11 US US15/349,554 patent/US20170058346A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010082039A1 (en) | 2010-07-22 |
| EP2492357A1 (en) | 2012-08-29 |
| US20110312524A1 (en) | 2011-12-22 |
| KR20110138341A (ko) | 2011-12-27 |
| US20160002722A1 (en) | 2016-01-07 |
| US20170058346A1 (en) | 2017-03-02 |
| EP2492357B1 (en) | 2015-09-23 |
| IL214154A0 (en) | 2011-08-31 |
| SG196843A1 (en) | 2014-02-13 |
| EP2387617B1 (en) | 2014-10-29 |
| EP2387617A1 (en) | 2011-11-23 |
| CN102356163A (zh) | 2012-02-15 |
| IL214154A (en) | 2016-10-31 |
| JP2012514994A (ja) | 2012-07-05 |
| CA2787218A1 (en) | 2010-07-22 |
| SG173042A1 (en) | 2011-08-29 |
| US9074241B2 (en) | 2015-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jathar et al. | Technological developments in lncRNA biology | |
| US20080076674A1 (en) | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer | |
| Nicholson et al. | Quantifying RNA binding sites transcriptome-wide using DO-RIP-seq | |
| US20170327866A1 (en) | Methods for in vivo identification of endogenous mrna targets of micrornas | |
| US20170058346A1 (en) | Methods Employing Non-Coding RNA Expression Assays | |
| De Cecco et al. | Measuring microRNA expression levels in oncology: from samples to data analysis | |
| Calin et al. | Investigation of microRNA alterations in leukemias and lymphomas | |
| Patnaik et al. | Expression of microRNAs in the NCI-60 cancer cell-lines | |
| Xicota et al. | Recommendations for pharmacotranscriptomic profiling of drug response in CNS disorders | |
| Zhu et al. | Comparison of gene expression measurements from cDNA and 60-mer oligonucleotide microarrays | |
| US20100255469A1 (en) | Cell monitoring and molecular analysis | |
| US12117437B2 (en) | Enhanced RNA interactome capture (eRIC) | |
| CN104774914B (zh) | 胆道闭锁及淤胆型婴儿肝炎综合征的microRNA血清标志物检测及其应用 | |
| Smirnova et al. | miRNA as a marker for in vitro neurotoxicity testing and related neurological disorders | |
| Assmann et al. | Transcriptomics to devise human health and disease | |
| Buzdin et al. | MicroRNA data for quantitative analysis of molecular pathways | |
| Gasparri et al. | A Robust siRNA Screening Approach with Optimized Conditions for Large-Scale Transfection in Multiple Human Cancer Cell Lines | |
| Wang et al. | Single-cell microRNA/mRNA co-sequencing reveals non-genetic heterogeneity and novel regulatory mechanisms | |
| Johnson et al. | Identifying Functional miRNA Targets Using Overexpression and Knockdown Methods | |
| Saha et al. | Future Directions and Challenges Involved in Cancer Noncoding RNomics | |
| Jäck et al. | MicroRNAs and Biomarker Discovery | |
| Vigano et al. | FEATURE ARTICLE & REVIEW |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |